Article summary
The passage of New Jersey Assembly Bill 3852, which creates a psilocybin therapy pilot program, exposed deep rifts between advocates seeking a medicalized pharmaceutical-led model and those supporting a community-based framework to regulate less costly psilocybin mushrooms. The post NJ Psilocybin Legislation Exposes Conflicts Between Advocates for Different Therapeutic Models first appeared on Lucid News. The post NJ Psilocybin Legislation Exposes Conflicts Between Advocates for Different Therapeutic Models appeared first on Lucid News.
Continue to the original publication for the complete article.